PortfoliosLab logo
Aelis Farma SA (AELIS.PA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

FR0014007ZB4

Highlights

Market Cap

€17.70M

EPS (TTM)

-€0.55

Total Revenue (TTM)

€7.45M

Gross Profit (TTM)

€4.12M

EBITDA (TTM)

-€8.00M

Year Range

€1.00 - €13.30

Target Price

€7.50

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Aelis Farma SA (AELIS.PA) returned -35.00% year-to-date (YTD) and -90.00% over the past 12 months.


AELIS.PA

YTD

-35.00%

1M

2.36%

6M

-57.52%

1Y

-90.00%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.77%

1M

7.44%

6M

-5.60%

1Y

8.37%

5Y*

14.12%

10Y*

10.46%

*Annualized

Monthly Returns

The table below presents the monthly returns of AELIS.PA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202560.00%-48.44%-24.24%-2.40%6.56%-35.00%
20243.05%-1.48%-2.63%0.39%1.54%-3.03%-7.03%-4.20%-62.28%-19.07%-22.41%-25.93%-84.73%
20232.95%1.87%-0.56%-0.50%-0.36%-0.36%-0.00%-1.43%-1.82%0.37%-1.11%-2.24%-3.25%
20225.40%3.16%-1.02%-9.59%-8.32%-2.49%-5.29%-0.77%-11.94%4.74%42.53%7.46%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AELIS.PA is 5, meaning it’s performing worse than 95% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of AELIS.PA is 55
Overall Rank
The Sharpe Ratio Rank of AELIS.PA is 1010
Sharpe Ratio Rank
The Sortino Ratio Rank of AELIS.PA is 22
Sortino Ratio Rank
The Omega Ratio Rank of AELIS.PA is 22
Omega Ratio Rank
The Calmar Ratio Rank of AELIS.PA is 11
Calmar Ratio Rank
The Martin Ratio Rank of AELIS.PA is 1212
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Aelis Farma SA (AELIS.PA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Aelis Farma SA Sharpe ratios as of May 11, 2025 (values are recalculated daily):

  • 1-Year: -0.82
  • All Time: -0.79

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Aelis Farma SA compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Aelis Farma SA doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Aelis Farma SA. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aelis Farma SA was 92.65%, occurring on Mar 26, 2025. The portfolio has not yet recovered.

The current Aelis Farma SA drawdown is 90.90%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-92.65%Feb 20, 2023536Mar 26, 2025
-37.95%Mar 18, 2022171Nov 15, 202258Feb 6, 2023229
-5.94%Feb 28, 20224Mar 3, 20229Mar 16, 202213
-4.76%Feb 21, 20221Feb 21, 20221Feb 22, 20222
-3.69%Feb 24, 20221Feb 24, 20221Feb 25, 20222

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Aelis Farma SA over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Aelis Farma SA, comparing actual results with analytics estimates.


-1.00-0.80-0.60-0.40-0.200.002022FebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember2023FebruaryMarch
-0.28
0
Actual
Estimate

Valuation

The Valuation section provides an overview of how Aelis Farma SA is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for AELIS.PA relative to other companies in the Biotechnology industry. Currently, AELIS.PA has a P/S ratio of 3.2. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for AELIS.PA in comparison with other companies in the Biotechnology industry. Currently, AELIS.PA has a P/B value of 1.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items